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ABSTRACT
Annexin-V is a cytosolic protein involved in many significant physiological roles including
stabilization of the phospholipid membrane, regulation of blood coagulation, and cell apoptosis or
programmed cell death. Though the exact mechanism of Annexin-V in the human body is not fully
understood, its wide range of applications in the medical field cannot be denied. Annexin-V can
be applied in cancer therapy as a diagnostic to detect cell apoptosis and determine the effectiveness
of chemotherapeutic drugs. Furthermore, Annexin-V could even be used as a drug delivery vehicle
in the treatment of cancer. Commercially useful proteins like Annexin-V are in high demand,
however, one big obstacle is that yielding a large amount of pure Annexin-V could be a tedious
and expensive procedure. Performing research with this protein could also become a huge financial
undertaking. The focus of this project was to study the optimal conditions by which the AnnexinV protein could be expressed, purified, and mass-produced. An additional goal was to devise a
cost-effective procedure of mass-producing Annexin-V. SDS-PAGE was the primary method
applied to test the intensity and purity of the Annexin-V sample yielded from experiments. SDSPAGE results establish that the E. coli over-expressed the Annexin-V protein. Purification using
an ion exchange (DEAE) column yielded Annexin-V of relatively high purity; a step-wise salt
gradient was significantly more effective than a linear salt gradient in eluting a more pure product
from the column. A bioreactor was used to perform batch fermentation. Three types of media were
used for the batch experiments: LB broth only, LB and 9 g/L glucose, and M9+glucose media
consisting of M9 salts, trace elements, biotin, and 9 g/L glucose. Among the batch fermentations,
LB and 9 g/L glucose yielded the highest amount of Annexin-V. However, the E. coli were not
able to successfully grow in the M9 media mixture. Additional experiments using the M9 media

3

will have to be performed to verify this observation. The data collected throughout this project
suggest that: 1) E. coli cultures are effective in over-expressing Annexin-V, 2) A DEAE
purification column, accompanied by the use of a step-wise salt gradient, yields Annexin-V of
considerably high purity 3) The use of LB/glucose media is an effective method to mass-produce
Annexin-V.

INTRODUCTION
Annexin-V is a member of a family of cytosolic proteins (Annexins) that have structural
similarities and are known to effectively bind to the phospholipid membrane. A key property that
all the proteins in the Annexin family share is their ability to bind to calcium. In fact, Annexins
are calcium-dependent proteins in that their binding affinity to the surface of phospholipids is
significantly reduced without the presence of calcium.3 In addition to their affinity to calcium, they
all preferentially bind to anionic phospholipids and have molecular weights of 35-40 kDA;
Annexin-V has a molecular weight of 36 kDa.7 Annexins consist of repeats of individual amino
acid domains that contribute to their high affinity to calcium and phospholipid ligands.8
Annexin-V is involved in many physiological roles including binding to the phospholipid
bilayer membrane and maintaining its integrity. Other roles include involvement in the processes
of endocytosis and exocytosis, enzyme inhibition, and anticoagulation.6 In particular, Annexin-V,
discovered in 1985, was first mainly known as a regulator of blood coagulation.3,4 The AnnexinV protein is used in many scientific experiments because the crystal structure of the human
recombinant Annexin-V protein has been established.1 The crystal structure of Annexin-V is
important because it facilitates the study of the phospholipid membrane-binding property of the
Annexin family of proteins. Another important reason that Annexin-V is a protein of great interest
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to researchers is because it plays a huge role in cell apoptosis.5 Due to the involvement of AnnexinV in the process of cell apoptosis, it has a wide array of applications in the fields of biotechnology
and pharmacy. Annexin-V attaches to the outer surface of cells undergoing apoptosis. Hence, it is
relatively easy to image the apoptotic cell if using fluorescently-labeled Annexin-V. This
technique of using radioactively-labeled human recombinant Annexin-V is very common, and is
widely used in clinical trials to image “ischemic injury, transplant rejection, and the response of
tumors to chemotherapeutic agents”.2 Annexin-V has also been proven to be useful as a mechanism
of drug delivery in the treatment of chronic diseases like cancer.
With the vast number of important physiological roles that Annexin-V is associated with,
the production of pure Annexin-V is in great demand. The production of a protein requires the use
of host cells. E. coli are often regarded as an effective host to produce recombinant proteins. This
is due to several factors: 1) The genetics and physiology of E. coli has been greatly studied, and
the manipulation of E. coli to yield recombinant DNA products has been widely applied, 2) It has
been demonstrated in many previous studies that expression of recombinant proteins using E. coli
could yield product levels that comprise of approximately 30 to 50% of total cellular protein, 3) E.
coli cultures are ideal for large-scale production of recombinant proteins because it can yield high
cell concentrations of over 100 g/L.9 There are a few disadvantages to using E. coli to produce
proteins like Annexin-V. These include the possible requirement of a large oxygen supply, as well
as the accumulation of metabolic by-products which could potentially inhibit E. coli growth.
However, the benefits of using E. coli to produce recombinant proteins like the human recombinant
Annexin-V greatly outweigh the disadvantages.
Using E. coli as an expression system would not be possible if it were not for the
development of genetic engineering or specifically recombinant DNA technology. The primary
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purpose of recombinant DNA technology is to genetically modify microorganisms such as E. coli
by implanting particular genes into them so that they can produce a useful product such as
Annexin-V. Recombinant DNA technology using E. coli requires the following steps: 1) The DNA
fragment coding for the protein of interest is synthesized or isolated, 2) An E. coli plasmid is
isolated and restriction endonucleases are used to cleave specific sites in the plasmid, allowing the
DNA fragment of the protein of interest to be inserted, 3) The recombinant DNA molecule is
directly introduced into E. coli cells via a process known as transformation, 4) The host cells that
have incorporated the recombinant DNA molecule are selected, cloned, and maintained to be used
in cultures for expression of the protein of interest.10
In order for proteins like Annexin-V to be commercially-applicable, they need to be
purified. There are many techniques used to purify proteins, with affinity chromatography and ion
exchange chromatography being frequently used ones. Polyhistidine tags or glutathione tags are
often used in an affinity chromatography procedure to purify proteins such as Annexin-V. The
general purpose of purification is to isolate the protein of interest from contaminant bacterial
proteins. There is a specific way in which affinity chromatography achieves this purpose. In order
to perform affinity chromatography, the protein of interest should already be tagged. In addition,
this procedure requires the use of a purification column with resin beads that would bind the tagged
protein. A concentrated solution of the tagged protein of interest is allowed to flow through the
column. At this time, high affinity binding occurs between the tagged protein and the resin.
Meanwhile, most of the contaminant proteins will be eluted out of the purification column. In order
to displace the protein bound to the resin and elute it out of the purification column, the column
has to be washed with an excess amount of an eluting buffer that can accomplish this task.
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Typically, increasing concentrations of sodium chloride or imidazole are used to serve this
purpose.11
Ion exchange chromatography is similar to affinity chromatography in that a purification
column with resin is necessary. Ion exchange is a protein purification procedure that is based on
reversible adsorption of charged molecules; usually, protein separation is achieved by using weak
exchangers or exchange resins that can bind to the charged protein of interest. In the case of
Annexin-V, which has an overall negative net charge, an anion-exchanger is most effective. A
DEAE-sepharose column, a purification column with anion exchanger dietylaminoethyl (DEAE)
is often used to purify anionic proteins like Annexin-V. DEAE-sepharose is a resin that is
essentially a matrix of chemically-modified and cross-linked agarose bead ions. DEAE-sepharose
is positively charged at neutral pH.12
In order for researchers and doctors to be able to use Annexin-V in clinical experiments,
and for pharmaceutical industries to take advantage of its medical uses by manufacturing it, largescale production of the Annexin-V protein is necessary. But, large-scale production is often a very
expensive procedure. Therefore, it is necessary to first determine which type of method is the most
cost-effective way of mass-producing the protein of interest. A bioreactor is the device typically
used to grow cultures for large-scale production of proteins. It can be operated in three different
modes: batch, fed-batch, and continuous. There are four important phases associated with growth
cultures: lag, log, stationary, and death. The culture in the bioreactor first goes through the lag
phase during which the cells are trying to adjust to the new environment and begin synthesizing
enzymes required to utilize the nutrients in the medium. Subsequent to this, the cells go through
exponential growth during the log phase. In the stationary phase, the cells begin to exhaust the
amount of nutrients necessary for their growth. And finally, in the death phase, there is a decrease
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in cell number. In a batch process, a cell culture is added to a sterile nutrient medium, and the host
cells (for example, E. coli) are allowed to grow in the bioreactor. There are not any other additions
to the culture, and the process is typically terminated during the stationary phase. A fed-batch
process is similar to a batch process except there is controlled addition of nutrient medium.
Typically, industrial processes manufacturing antibiotics use fed-batch processes because
controlling the supply of nutrients (which can be accomplished by varying the feed rate, for
example) allows for greater control of cell growth. In addition to the feed rate, other variables can
varied such as the pH and the dissolved oxygen level. Fed-batch processes are also sometimes
preferred because it is economically practical; the total mass of culture increases during fed-batch
operation, and this usually correlates to greater yield of the protein of interest. In a continuous
process, the amount of nutrients necessary for cell growth is continuously fed into the bioreactor;
a certain amount of culture is also continuously withdrawn from the bioreactor. Other than factors
such as the mode of operation, temperature, pH, feed rate, and the dissolved oxygen level, the type
of nutrient medium used could also be experimented with. Varying such factors could help in
optimizing the yield of the protein of interest, and in determining a cost-effective procedure to
produce the protein.13

MATERIALS AND METHODS
Expression of Annexin-V using E. coli:
An overnight culture was prepared by swirling one colony of E. coli containing the Annexin-V
gene in 5 mL of LB media. About 12 µL of 50 mg/mL ampicillin was added to the culture. The
strain of E. coli used was engineered to be ampicillin-resistant so addition of ampicillin prevents
the growth of contaminant microorganisms. The overnight culture was then placed in the
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incubator-shaker at 37ºC. The following day, the overnight culture was added to 100 mL of LB
media and approximately 200 µL of ampicillin. The optical density of the E. coli culture was
periodically checked using a Beckman Coulter DU 800 spectrophotometer at a wavelength of 600
nm. After the E. coli culture reached an optical density of about 0.3-0.4, IPTG, isopropyl-beta-Dthiogalactopyranoside, to induce expression of Annexin-V. After approximately three hours, the
cell culture was centrifuged at a speed of approximately 4200 rpm for 45 minutes. A small sample
of the supernatant was collected in an Eppendorf tube, while the rest of the volume was decanted.
The collected sample as well as the pellet was stored in a -80ºC freezer until analysis using SDSPAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis). On the day in which SDSPAGE is performed, a gel was prepared for the analysis of the samples collected during expression.
Blue dye with beta-mercaptoethanol was added to all the samples, and heated. The samples, as
well as a molecular protein marker were then loaded onto the gel. Subsequent to this, SDS-PAGE
was initiated at a voltage of 200 V. After staining and de-staining the resulting gel, it was checked
for expression of Annexin-V.
Purification of Annexin-V using DEAE-sepharose column:
Prior to purification of Annexin-V, the E. coli pellet obtained after expression was pre-treated. The
pellet was re-suspended in cold 50 mM Tris HCl, 10 mM CaCl2 at pH 7.2. The pellet slurry, placed
in an ice bath, was sonicated to yield a homogeneous pellet mixture. Then, the pellet slurry was
centrifuged for 20 minutes at 4ºC and a speed of 4200 rpm. After collecting a small amount of the
supernatant for analysis, and discarding the rest, the pellet was re-suspended in 50 mM Tris HCl
20 mM EDTA at pH 7.2. The EDTA causes the Annexin-V protein to be released from the pellet
into the supernatant. This pellet slurry was again centrifuged at the same conditions as stated
above. The supernatant collected after centrifugation was dialyzed in 20 mM Tris HCl at pH 8.0
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and at 4ºC. The next day, the DEAE-sepharose column was set up and first equilibrated with a
buffer that is a 1:10 dilution of the dialysis buffer. Then the dialyzed supernatant was pumped into
the purification column. The purification column was connected to a chromatograph to visually
detect peaks corresponding to the amount of protein eluted. Soon after the Annexin-V dialysis
buffer is pumped into the column, a large contaminant peak should be observed. This is when a
salt gradient was used to elute the Annexin-V protein out of the purification column. Both a linear
salt gradient as well as a step-wise salt gradient were used. To establish a linear salt gradient, a
gradient salt mixer was applied. For the step-wise gradient, increasing concentrations of sodium
chloride solution were used: 100 mM NaCl, 200 mM NaCl, 300 mM NaCl, 400 mM NaCl, 500
mM NaCl, and 1 M NaCl. Each salt solution was individually pumped into the column, starting
from 100 mM NaCl. If a peak is observed on the chromatograph, it is indicative of some of the
Annexin-V being eluted from the resin in the purification column. Hence, samples were collected
whenever peaks were observed. Guanidinium hydrochloride was pumped into the column as well,
and a sample was collected. All the collected samples were stored in -80ºC until SDS-PAGE
analysis. The purification column itself, at the end of the purification experiment, was regenerated
using milliQ water and 20% ethanol.
Fermentation using a Bioreactor:
A 5 mL overnight culture was prepared similar to the first step of the Annexin-V expression
experiment. A 100 mL pre-culture was prepared the following day. The bioreactor was sterilized
for use the day after. A 1 L medium with the 100 mL pre-culture from the previous day was
prepared for E. coli growth in the bioreactor. A bioreactor with an ADI 1010 bio controller and an
ADI 1025 bio console was adjusted at a rotor speed of 700 and a temperature of 37ºC. Air was
continuously supplied to the bioreactor. The optical density of the E. coli culture was frequently
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checked to see if a value of 0.3 or 0.4 was reached, at which time the culture was induced with 3
mM IPTG. After a 3-hour induction period, the operation of the bioreactor was terminated, and
the cell culture was centrifuged at a temperature of 4ºC and a speed of 4200 rpm. The resulting
pellet was stored in -80ºC until SDS-PAGE and densiometry were performed.

RESULTS
The SDS-PAGE results from the expression of Annexin V, shown in Figures 1 and 2,
established that Annexin-V has been successfully expressed by the E. coli. Experiments performed
in the Beitle laboratory have indicated that the optimum IPTG concentration to add to the E. coli
culture is 3 mM, and the ideal induction time is approximately 3 hours.

36 kDa,
Annexin-V

Figure 1. Expression SDS-PAGE
1: Molecular Marker
2: Supernatant
3: Pellet
4: Induced pellet
5: Un-induced pellet

Figure 2. Expression SDS-PAGE
1: 10 mM induced (pellet)
2: 10 mM induced (supernatant)
3 3 mM induced (pellet)
4: 3 mM induced (supernatant)
5: Un-induced (pellet)
6: Un-induced (supernatant)
7: Protein Marker
11

As Figure 3 demonstrates, as expected, the EDTA solution caused the Annexin-V protein
to be released into the supernatant from the pellet. Purification of Annexin-V was performed using
the DEAE-sepharose column, and applying two different techniques to elute the protein from the
column: linear salt gradient and step-wise salt gradient. The SDS-PAGE results for the linear salt
gradient are shown in Figure 4, while those for the step-wise salt gradient are shown in Figure 5.
Though both techniques yielded reasonably pure Annexin-V, the latter was more effective. The
SDS-PAGE from the purification experiment using a step-wise salt gradient demonstrates that
virtually all the Annexin-V protein is eluted out of the purification column at a NaCl concentration
of 200 mM. Visually, it appears that purification via a DEAE column and a step-wise salt gradient
yields Annexin-V with a purity of over 90%.

Figure 3. Tris/EDTA and
Dialysis
(PM indicates “Protein Marker”)
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Figure 4. Purification SDS-PAGE
with Linear Salt Gradient
(Gdn-HCl indicates “Guanidinium
hydrochloride)

Figure 5. Purification SDS-PAGE
with Step-wise salt gradient
(200 mM indicates 200 mM
NaCl)

Batch fermentation experiments were performed using the bioreactor. The parameter that was
varied was the type of medium used. Three different types of media were used: LB medium, LB
medium plus glucose, and M9 salts+glucose medium. Annexin-V was successfully mass-produced
in LB medium and LB plus glucose medium. According to the results from the densiometry test
13

using the SDS-PAGE shown in Figure 6, the protein yield in LB medium was 28%, while it was
approximately 16% greater in the LB+ glucose medium.

Figure 6. SDS-PAGE Batch
Fermentation
1: Protein Marker
2: LB Medium CaCl2 Pellet
3: LB Medium EDTA Pellet
4: LB+9 g/L glucose CaCl2 Pellet
5: LB+9 g/L glucose EDTA Pellet

Figure 7. Densiometry Plot
Peaks from left to right
correspond to lanes 2-5 in SDSPAGE shown above
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DISCUSSION
The data collected from the experiments performed establish that an E. coli culture induced with
3 mM IPTG successfully expresses the Annexin-V protein. The DEAE-exchange column is an
effective purification column for the purification of Annexin-V. This column was used because it
allows for a simple purification protocol since it functions primarily based on the opposite charges
of the DEAE-resin and the Annexin-V protein. The step-wise salt gradient was quite successful in
the goal of yielding Annexin-V of significantly high purity. In the future, the purification
experiments using glutathione or polyhistidine-tagged Annexin-V will be performed in the Beitle
laboratory to determine whether a more optimal protocol could be applied with regard to producing
Annexin-V of higher purity. Mass-production of Annexin-V using E. coli cultures grown in a
bioreactor can be achieved. LB plus 9 g/L glucose medium yielded a greater amount of AnnexinV compared to just LB medium. This is consistent with common knowledge because glucose acts
as an additional source of nutrients for the E. coli, effectively allowing it to produce more of the
Annexin-V protein. Additional experiments using the M9 salts+glucose medium will be performed
to evaluate whether this medium can be used to mass-produce Annexin-V. Fed-batch fermentation
will also be performed in the Beitle laboratory to determine if this procedure offers a significantly
higher amount of Annexin-V compared to batch fermentation. Another goal of the Beitle
laboratory with regard to the continuation of this project is to perform several different biophysical
experiments to characterize the Annexin-V protein including thermal denaturation, circular
dichroism, trypsin digestion, isothermal titration calorimetry, NMR spectroscopy, and tests to
determine the apoptotic activity of the Recombinant Annexin V.
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